Annual report pursuant to Section 13 and 15(d)

Balance Sheet

v2.4.0.6
Balance Sheet (USD $)
Dec. 31, 2011
Dec. 31, 2010
Current Assets:    
Cash and cash equivalents $ 9,861,488 $ 12,340,239
Marketable securities (note 4) 1,950,000 2,451,620
Research tax credit receivable (note 16) 0 145,513
Prepaid expenses and other current assets (note 5) 333,171 706,649
Note receivable - current portion (note 6) 18,682 28,023
Total Current Assets 12,163,341 15,672,044
Restricted Cash Equivalents (note 15) 1,431,765 401,893
Note Receivable (note 6) 0 18,682
Equipment, Net (note 7) 94,542 123,565
Total Assets 13,689,648 16,216,184
Current Liabilities:    
Accounts payable and accrued expenses (note 8) 1,185,405 1,820,900
Deferred Research and Development Arrangement (note 9) 825,000 900,000
Other Liabilities (note 10) 104,388 133,117
Warrant Liabilities (note 13) 868,725 2,966,710
Total Liabilities 2,983,518 5,820,727
Commitments and Contingencies (note 16)      
Stockholders' Equity (note 11):    
Preferred stock, par value $0.0001, 100,000,000 authorized shares, none issued and outstanding 0 0
Common stock, par value $0.0001, 500,000,000 authorized shares, 95,359,861 (2010 - 84,175,054) issued and 95,345,656 (2010 - 84,160,849) outstanding 9,536 8,418
Additional paid-in capital 67,809,617 56,157,452
Accumulated other comprehensive loss 0 (2,340)
Accumulated deficit during the development stage (57,084,613) (45,739,663)
Treasury stock, 14,205 shares, at cost (28,410) (28,410)
Total Stockholders' Equity 10,706,130 10,395,457
Total Liabilities and Stockholders' Equity $ 13,689,648 $ 16,216,184